secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001493152-23-010315
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Therapeutics reports FY2022 net loss of $10.5M; cash only $0.7M, substantial doubt about going concern
--------------------------------------------------------------------------------

- Net loss of $10.5M ($0.28 per share) in FY2022 vs $8.7M ($0.23) in FY2021.
- Cash and restricted cash only $0.7M; owes Juvenescence $21.4M in loans.
- Substantial doubt about ability to continue as a going concern for next 12 months.
- Operating expenses fell to $7.0M from $8.2M; R&D decreased to $1.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/0001493152-23-010315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer